With the growth momentum hit hard by the notes ban, Nomura had earlier projected GDP growth to dip to 6.9 per cent in 2017 from 7.1 per cent in 2016, with a sharp slowdown in the first half of the current year.
Some of the key Indian companies have been sceptical about Trump's stress on protectionism, including the IT industry. IT industry body Nasscom has been wary about Trump's statement on visa-related issues.
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc.
Citing IMS MAT September 2016 data, the company said MS Contin ER tablets had sales of USD 282.9 million in the US market.
India's healthcare industry is on a high growth trajectory having evolved significantly in past decade.
Government proposes to add 3,000 pharmacies under the Jan Aushadhi Yojana.
The product is expected to be launched in the first quarter of the next fiscal.
She made a strong case for adequately staffing the drug control administration.
The USFDA had taken action against companies like Sun Pharma and Ranbaxy.
Dabur is planning to commercially produce the drugs within 6 months.
Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals.
Government had recently withdrawn duty exemptions on 74 drugs.
The CBEC has recently withdrawn exemption on as many as 74 drugs.
She requested the Centre to increase S&T investments as it is India's future.